kras
No description yet: the sentence for this tag has not been written. 3 records carry it: 2 biomarkers, 1 person.
Related tags
By kind
3 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Ferdinandos Skoulidis Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy. | Non-small-cell lung cancer | none | lung, targeted-therapy | ||
KRAS G12C KRAS KRAS G12C swaps glycine 12 for cysteine and was the first KRAS mutation a drug could grip. Sotorasib and adagrasib are approved for it in lung cancer, and with an EGFR antibody in bowel cancer. | Non-small-cell lung cancer, Colorectal cancer, Pancreatic ductal adenocarcinoma | none | biomarker | ||
KRAS G12D (and other non-G12C KRAS mutations) KRAS G12D is the commonest KRAS mutation, especially in pancreatic cancer, and has no approved drug yet. In bowel cancer any KRAS or NRAS mutation is a reason not to give EGFR antibodies, which is where the approvals sit. | Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer | none | biomarker |